Search Results
Jun 25, 2026, 11:35 ET Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
NEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive
More news about: Oramed Pharmaceuticals Inc.
Jun 17, 2026, 08:55 ET Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small
More news about: Oramed Pharmaceuticals Inc.
Jan 13, 2026, 07:58 ET Oramed and Lifeward Announce Strategic Transaction
NEW YORK, Jan. 13, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed") and Lifeward Ltd. (NASDAQ: LFWD) ("Lifeward") today announced the signing of binding agreements for a strategic transaction between
More news about: Oramed Pharmaceuticals Inc.
Jan 07, 2026, 08:55 ET Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option
More news about: Oramed Pharmaceuticals Inc.
Nov 17, 2025, 08:56 ET Oramed Reports Fiscal Third Quarter 2025 Financial Results
NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited
More news about: Oramed Pharmaceuticals Inc.
Nov 17, 2025, 08:50 ET ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
About Oramed Pharmaceuticals Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Oramed's novel Protein
More news about: Oramed Pharmaceuticals Inc.
Oct 23, 2025, 08:55 ET Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a clinical-stage pharmaceutical company, today issued a Letter to Shareholders from its President and Chief
More news about: Oramed Pharmaceuticals Inc.